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Abstract
Background: Heterozygous Familial Hypercholesterolemia (FH) is a genetic disorder characterized by a high risk of
cardiovascular disease. Certain polymorphisms of the factor VII gene have been associated with the development
of coronary artery disease and there is a known association between factor VII levels and polymorphic variants in
this gene. To date, no study has evaluated the association between factor VII and coronary artery disease in
patients with FH.
Results: This case-control study comprised 720 patients (546 with FH and 174 controls). We determined the
prevalence and allele frequencies of the R353Q polymorphism of factor VII, the plasma levels of factor VII antigen
(FVII Ag) and whether they could be predictive factors for cardiovascular risk. 75% (410) of the patients with FH
were RR, 23% (127) RQ and 1.6% (9) QQ; in the control group 75.3% (131) were RR, 21.3% (37) RQ and 3.4% (6) QQ
(p = 0.32). No statistically significant associations were observed in the distribution of genotypes and allele
frequencies between case (FH) and control groups. Nor did we find differences when we evaluated the
relationship between the R353Q polymorphism and cardiovascular risk (including coronary disease, ischemic stroke
and peripheral arterial disease), either in the univariate analysis or after adjustment for sex, age, arterial
hypertension, body mass index, xanthomas, diabetes, smoking, HDLc and LDLc and lipid-lowering treatment. The
FVII Ag concentrations behaved in a similar fashion, with no differences for the interaction between controls and
those with FH (RR vs. RQ/QQ; p = 0.96). In the subgroup of patients with FH no association was found among
cardiovascular disease, genotype and FVII Ag levels (RR vs. RQ/QQ; p = 0.97).
Conclusions: Our study did not find a direct relationship between cardiovascular risk in patients with
Heterozygous Familial Hypercholesterolemia, the R353Q polymorphism of factor VII and FVII Ag levels.
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Bakground
Heterozygous Familial Hypercholesterolemia (FH) is an
autosomal codominant disease caused by defects in the
low-density lipoprotein receptor (LDLR) gene [1]. It is a
genetic disorder characterized by elevated levels of
plasma low-density lipoproteins cholesterol (LDLc)
ranging from 300 to 400 mg/dl, corneal arcus, tendon
xanthomas and a high prevalence of early-onset coron-
ary disease. It is extremely heterogeneous, with an inci-
dence of one in 500 persons (0.2%) [2,3]. The study of
the mechanisms that encourage the development of car-
diovascular disease (CVD) is of great interest, given the
variability both of the clinical picture and in the thera-
peutic response that characterizes this disease. More-
over, not all diagnosed patients present clinical
symptoms, so a better understanding of the factors that
lead to some patients developing early-onset CVD while
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ating the risk and adopting preventive measures.
In patients at high CVD risk, such as patients with
FH, there appears to be a chronic activation of the
mechanisms of coagulation and hemostasis, which leads
to what is regarded as a permanent prothrombotic con-
dition [4,5]. Thrombosis is the basis of the most acute
manifestations of coronary artery disease. The athero-
matous plaque rupture, with the consequent exposure of
tissue factor to blood and its subsequent union with fac-
tor VII (FVII), initiates the coagulation cascade [6]. One
of the components of hemostasis that has aroused inter-
est for its potential role in the development of coronary
disease and stroke is FVII. Some studies have associated
high levels of plasma FVII with an elevated risk of cor-
onary artery disease [7-10], although these findings have
not been confirmed by other studies leading to highly
variable results [11,12]. The R353Q polymorphism of
the FVII gene has been among those most closely asso-
ciated with variations in plasma levels of FVII [13-16].
This is a simple nucleotide polymorphism (SNP), char-
acterized by the substitution of a guanine base by an
adenine, which involves the substitution of arginine (R)
by glutamine (Q) in codon 353 of this protein [8].
Lower levels of FVII have been detected in carriers of
the Q allele than in individuals who are homozygous for
the more common R allele [17,18]. Carriers of the Q
allele may therefore be protected against acute thrombo-
tic events, as has been demonstrated by a number of
case-control studies in which the Q allele was associated
with a reduced risk of acute myocardial infarct [19-24];
however, this association was weaker [25] or was not
detected in another studies [26-28].
The principal objectives of this study were therefore to
analyze the prevalence and allele frequency of the
R353Q polymorphism and the plasma FVII levels in FH
patients with or without CVD and in family members
who were unaffected by FH (controls), and to determine
whether the presence of this polymorphism could be a
predictor of CVD risk in these patients.
Material and methods
Study design and study population
This was a case-control study of a sample population
selected from a Spanish FH Longitudinal Cohort Study,
supported by the “Fundación Española de Hipercolester-
olemia Familiar” http://www.colesterolfamiliar.com.O n e
person per familiy (index case) was also included. The
clinical diagnosis of FH was made in accordance with
the diagnostic criteria homogenized by the MEDPED
international cooperative program, which is coordinated
by the World Health Organization (WHO) [29]. All
patients with FH included in the study were heterozy-
gous carriers for known functional mutations in the
LDLR gene. This FH genetic diagnosis was carried out
also in control patients, assuring the no-FH diagnosis. A
written informed consent was obtained from all partici-
pants before their inclusion in the cohort and the proto-
col was approved by the ethic committee of the CEIC
Fundación Jiménez Díaz (Madrid). STREGA criteria
were used in the reporting of our study [30,31].
We determined the polymorphism in 720 patients.
Among them there were 546 persons affected by FH
(cases) and 174 family members unaffected by FH (con-
trols). Clinical data concerning sex, age, history of arter-
ial hypertension (HT), smoking, diabetes mellitus (DM),
body mass index (BMI), xanthomas, total cholesterol
level, triglycerides, LDLc, high-density lipoproteins cho-
lesterol (HDLc), treatment for hyperlipemia and CVD
were collected.
Cardiovascular events
The evaluation and definition of CVD events was based
on the WHO MONICA project [32]. CVD was classified
as “early onset” when it occurred at an age of less than
55 years in men and 65 in women. CVD events were
evaluated via analysis of the CVD history of the patient
himself and those of his first-degree (parents, siblings
and children) and second-degree (grandparents, aunts
and uncles, cousins and nieces and nephews by blood)
family who had a documented clinical history of a)
ischemic cardiopulmonary (myocardial infarct, angina
pectoris, surgery or any other coronary revascularization
procedure), b) cerebrovascular disease or c) peripheral
vascular disease.
Sampling procedures
On enrollment in the study, blood samples were
obtained by venous puncture from fasting patients. Sam-
ples were sent to a central laboratory for the extraction
of genomic DNA from the leukocyte fraction of fresh
blood, using the Puregen
® (DNA isolation kit, Gentra
Systems, MN, U.S.A). The genomic DNA was used for
the determination of the R353Q mutation of the FVII
coagulation gene.
Determination of FVII polymorphism
FVII polymorphism was determined according to Lind-
man et al. [33], by real-time polymerase chain reaction
(RT-PCR) (Stratagene Mx3005P Cultek) of a DNA
region of exon 8 of the FVII coagulation gene. We used
150 ng of genomic DNA, 3 mM of MgCl2, 200 μMo f
each nucleotide, 1 IU of Hot Start polymerase and reac-
tion buffer to 1X (Dominion-MBL).
The primers were mixed with the probe
(GATGCCCGTCAGGTACCACGTGCCC (C/T) GGTA
GTGGGTGGCATGTGGGCCTCC) to 1X in a final
volume of 10 μl (Taqman
®-Applied Biosystems). The
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cycles of denaturation at 95°C for 30 s, a phase of pri-
mer-polymerase union (60°C for 1 min) and extension
(72°C for 30 s). The population genotypes were subse-
quently analyzed using the curves supplied by the RT-
PRC equipment. In the R353Q assay, a guanine base is
replaced by an adenine, which requires the substitution
of arginine (R) by glutamine (Q) in codon 353 of this
protein.
Standard good laboratory practices were undertaken
to ensure the accuracy of genotype data, including the
inclusion of dummy duplicates.
Determination of plasma FVII Ag concentrations
FVII Ag levels were determined using an Elisa Kit
(AssayMax Human Factor VII ELISA Kit
®, Assaypro)
with a minimum detectable dose < 6 ng/ml and an intra
and inter-assay coefficients of variation of 5.0 % and
7.1% respectively.
Quantification of plasma lipid levels
Plasma lipid levels (mg/dl) were determined by spectro-
photometry (enzymetric colorimetry) in a Modular Ana-
lytics ISE-4-DDPPEEPP autoanalyzer (F. Hoffmann-La
Roche, Basle, Switzerland); an oxidation-peroxidation
method was employed to assay total cholesterol, HDLc
and triglycerides; LDLc was estimated by Friedewald’s
formula (LDLc = total cholesterol - triglycerides/5-
HDLc).
Statistical analysis
The SPSS statistical package (version 17.0 for Windows)
was utilized for all statistical analyses, which comprised:
- descriptive analysis of absolute and relative fre-
quencies with 95% confidence intervals (CI) and
means and standard deviations of the quantitative
variables.
- comparison of qualitative variables using chi-
squared contingency tables; in the case of 2 × 2
tables, the chi-squared table alone was used, while if
any expected frequency was < 5, Fisher’s exact test
was employed.
- comparisons of the mean values of the quantitative
variables by means of Student’s t-test for two inde-
pendent samples or single-factor analysis of variance
for more than two independent samples.
In all the statistical tests, values of p < 0.05 were trea-
ted as significant and the hypothesized contrasts were
bilateral.
In order to evaluate the association of the FVII geno-
type with CVD, we calculated the odds ratio (crude OR)
and its 95% CI by univariate logistical regressions. In
order to control for sex, age, HT, BMI, xanthomas, DM,
LDLc, HDLc, smoking and lipid-lowering therapy, we
employed a multivariate logistics model (adjusted OR).
Results
Baseline characteristics
The general characteristics of the patients are shown in
T a b l e1 .N os i g n i f i c a n td i f f e r e n c e sw e r ef o u n di nt h e
following variables: sex, BMI, HT, DM or triglyceride
levels between the FH and control groups. However
t h e r ew e r ed i f f e r e n c e si na g e, total cholesterol, LDLc
and HDLc levels, xanthomas (102 of 546 HF patients
developed them, 18.9%), in those patients under lipid-
lowering treatment (more than 83% of the FH), in the
number of CVD events as well as in global CVD and in
the mean age of the first event.
Cardiovascular disease
In 14.7% of the patients with FH a CVD event occurred;
75 patients developed coronary artery disease, 4 cerebro-
vascular disease and 12 peripheral arterial disease. In the
distribution by vascular territories, 71% of FH with CVD
had affectation of a single territory while in 9%, two or
more territories were affected, with a statistically signifi-
cant difference in the distribution of the CVD events
compared with the control group (p < 0.001). We must
emphasize the low frequency of cerebrovascular disease
in both the control (1.7%) and the FH group (0.7%),
with no significant difference between them (p = 0.37).
The frequency of peripheral vascular disease (predomi-
nantly in the lower extremities) was 2.1% in FH patients
and 0.5% in the controls (p = 0.21).
The R353Q polymorphism
In the analysis of the R353Q genotypes distribution
(Table 2), we found that 75.1% of the patients with FH
were RR, 21.3% were RQ and 3.4% QQ, without any evi-
dence of differences between the control and FH groups
(p = 0.32). Similar results were obtained when we ana-
lyzed this genotypes distribution comparing RR vs RQ/
QQ (p = 0.96). In the allele frequencies (R or Q allele
presence), we found no statistically significant differ-
ences between case (FH) and control groups (0.86 and
0.87, IC 95% 0.82, 0.89 and 0.85, 0.89 respectively for
the R allele; 0.14 and 0.13, IC 95% 0.11, 0.18 and 0.11,
0.15 respectively for the Q allele). The allele frequencies
in both were adjusted to the Hardy-Weinberg equili-
brium (p = 0.97 and p = 28, respectively).
Polymorphism and cardiovascular risk
In order to identify possible relationships between the
different genotypes and higher or lower prevalence of
CVD in FH patients (Table 3), we performed an univari-
ate analysis. With respect to global CVD we found no
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genotypes, just as in those subjects who were homozy-
gous for the non-dominant gene (RR genotype). The
separately analysis of coronary artery disease and per-
ipheral vascular disease led to same results; this analysis
could not be applied to cerebrovascular disease because
of its low incidence (four subjects). Multivariate logistic
regression analysis, adjusted for sex, age, HT, BMI,
xanthomas, DM, HDLc, LDLc, smoking habit and treat-
ment for hyperlipemia found no association between the
genotypes of the FVII R353Q mutation and CVD.
FVII Ag levels
Plasma FVII Ag levels (ng/mL) were determined in a
subgroup of 320 patients, 160 controls (including 8 with
CVD) and 160 FH patients (80 with CVD). The geno-
types distribution (RR vs RQ/QQ) between both groups
was similar (p > 0.05). Analysis of variance for two fac-
tors (FH and genotype) adjusted for sex, age, DM,
smoking, HT and CVD was applied and no differences
were found in FVII Ag levels for the interaction between
both factors (p = 0.96) (Table 4). We also studied the
F V I IA gc o n c e n t r a t i o ni np a t i e n t sw i t hF H( n=1 6 0 )
Table 1 Basic characteristics of patients and controls
Controls N = 174 Familial hypercholesterolemia N = 546 Value of P
Age (years) 39.7 ± 17.5 43.5 ± 16.3 0.009
Women (%) 55.7 47.3 0.62
BMI 25.7 26.6 0.20
HT (%) 10.3 12.7 0.41
DM (%) 2.3 2.4 1.000
Total cholesterol (mg/dl) 239.6 ± 70.3 270.3 ± 70.4 < 0.001
Triglycerides (mg/dl) 102.2 ± 61.1 109.1 ± 62.5 0.22
LDLc (mg/dl) 168.4 ± 68.4 201.3 ± 67.1 < 0.001
HDLc (mg/dl) 50.2 ± 13.4 46.1 ± 13.2 < 0.001
Xanthomas 0.0 102 (18.6%) < 0.001
Smoking (%) 46.8 49.4 0.55
Lipid-lowering treatment 66 (37.9%) 458 (83.9%) < 0.001
CV disease 8 (4.6%) 80 (14.7%) < 0.001
First CV event (years) 57.1 ± 13.3 46.7 ± 11.1 0.01
Coronary artery disease 6 (3.4%) 75 (13.7%) < 0.001
Cerebrovascular disease 3 (1.7%) 4 (0.7%) 0.37
Peripheral arterial disease 1 (0.5%) 12 (2.1%) 0.21
CVD distribution:
-single territory 6 (3.5%) 71 (13%) < 0.001
-two or more territories 2 (1.2%) 9 (1.6%)
Values expressed as means ± standard deviation. BMI: body mass index, calculated by dividing weight by height squared. HT: arterial hypertension. DM: diabetes
mellitus. CV: cardiovascular. LDLc: low-density lipoproteins cholesterol. HDLc: high-density lipoproteins cholesterol.
Table 2 FVII genotype polymorphisms of FH and control patients
Controls N = 174 Familiar hypercholesterolemia N = 546 Total N = 720 Value of P*
Genotype
R353Q FVII
0.32
RR 131 (75.3%) 410 (75.1%) 541 (75.1%)
RQ 37 (21.3%) 127 (23.3%) 164 (22.8%)
QQ 6 (3.4%) 9 (1.6%) 15 (2.1%)
0.96
RR 131 (75.3%) 410 (75.1%) 541 (75.1%)
RQ/QQ 43 (24.7%) 136 (24.9%) 179 (24.9%)
Allele frequency
R 0.86 (0.82-0.89) 0.87 (0.85-0.89)
Q 0.14 (0.11-0.18) 0.13 (0.11-0.15)
*P values expressed by c2 (Pearson). FVII: Factor VII.
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sis of variance for CVD and genotype adjusted for age,
sex, DM, smoking and HT no differences were found
for the interaction between them (p = 0.97) (Table 5).
Discussion
In our study, the R353Q polymorphism of the FVII
gene, its allele frequency and the FVII Ag levels neither
predict nor are directly related to the prevalence of
CVD in FH patients.
FH is the monogenetic disease with the highest preva-
lence in human beings and it is associated with a high
risk of early and serious CVD. The global prevalence of
CVD in this study was 14.7%, with a mean age of 45.5 ±
16.3 years, while it is estimated that in general spanish
population the prevalence in the same age range is 2.6%
[34]. The prevalence of FH is highly variable in western
populations, being as high as 39% in some series [35].
These variations have been attributed to a number of
factors, such as the different diagnostic criteria (genetic
or clinical) used in the FH studies, differences in the
methodologies employed and the possible direct influ-
ence of environmental factors, such as diet. In fact, it
has been demonstrated that consumption of a Mediter-
ranean diet rich in olive oil reduces the incidence of
CVD in the general population [34], even leading to a
Table 3 Multivariate analysis of FH patients
CVD Patients (%)
Patients
(n = 546)
No
(n = 466)
Yes
(n = 80)
OR (CI 95%)* P Adjusted OR** (CI 95%) P
FVII
RR 410 350 (75.1) 60 (75.0) 1.00 (Reference) 1.00 (Reference)
RQ 127 110 (23.6) 17 (21.3) 0.89 (0.50 - 1.59) 0.70 0.76 (0.36 - 1.58) 0.46
QQ 9 6 (1.3) 3 (3.7) 2.88 (0.70 -11.84) 0.14 3.53 (0.66 - 18.92) 0.14
RQ/QQ 136 116 (24.9) 20 (25.0) 0.99 (0.58 - 1.72) 0.98 0.89 (0.45 - 1.78) 0.75
CAD Patients (%)
Patients
(n = 546)
No
(n = 471)
Yes
(n = 75)
OR (CI 95%)* P Adjusted OR** (CI 95%) P
FVII
RR 410 354 (75.1) 56 (74.7) 1.00 (Reference) 1.00 (Reference)
RQ 127 111 (23.5) 16 (21.3) 0.90 (0.50 - 1.63) 0.73 0.90 (0.43 - 1.87) 0.77
QQ 9 6 (1.4) 3 (4.0) 3.12 (0.76 -12.86) 0.11 3.33 (0.64 - 17.24) 0.15
RQ/QQ 136 117 (24.9) 19 (24.3) 1.02 (0.58 - 1.78) 0.96 1.05 (0.52 - 2.08) 0.90
PAD Patients (%)
Patients
(n = 546)
No
(n = 534)
Yes
(n = 12)
OR (CI 95%)* P Adjusted OR** (CI 95%) P
FVII
RR 410 401 (75.1) 9 (75.0) 1.00 (Reference) 1.00 (Reference)
RQ 127 125 (23.4) 2 (13.7) 0.71 (0.15 -3.34) 0.67 0.78 (0.15 - 3.84) 0.76
QQ 9 8 (1.5) 1 (8.3) 5.56 (0.63 -49.33) 0.12 5.77 (0.26 - 125.96) 0.26
RQ/QQ 136 132 (24.9) 3 (24.0) 1.00 (0.27 - 3.77) 0.99 1.03 (0.26 - 4.17) 0.96
*Crude OR obtained by univariate logistic regression analysis. **Multivariate logistic regression adjusted for sex, age, body mass index, xanthomas, arterial
hypertension, smoking, diabetes mellitus, LDLc, HDLc and lipid-lowering treatment. FVII: Factor VII. FH: Heterozygous Familial Hypercholesterolemia. CVD:
cardiovascular disease. CAD: coronary artery disease. PAD: peripheral artery disease.
Table 4 FVII Ag levels in controls and FH patients
Controls (n = 160) Familiar hypercholesterolemia (n = 160)
Genotype
R353Q FVII
FVII levels
(ng/mL)
RR (n = 120) Mean 374.6 ± 239.6 292.8 ± 157.6
Adjusted mean 372.9 ± 204.7 288.6 ± 211.2
RQ/QQ (n = 40) Mean 387.5 ± 248.2 265.6 ± 130.8
Adjusted mean 376.7 ± 198.1 293.9 ± 200.2
Values expressed as means ± standard deviation. Analysis of variance for two factors (FH and genotype) adjusted for age, sex, diabetes, smoking, arterial
hypertension and cardiovascular disease. No differences were found for the interaction between both factors (0.96). FVII: Factor VII.
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would also have a direct influence on subjects with FH.
The phenotypic expression of FH in terms of onset and
severity of atherosclerotic vascular disease varies consid-
erably. A paucity of consistent data exist on factors that
contribute to these phenotypic differences. Several stu-
dies have analyzed the influence of traditional CVD risk
factors and the functional variety of LDLR mutation on
this phenotypic variability [38,39]. However, they can
only partially explain the observed differences. Therefore
other still unknown factors, such as genetic conditions,
could play an important role in the development of
CVD in these patients. This is sustained by the fact that
clustering of CVD occurs in FH kindred. The genetic
variability of this population sample would be deter-
mined by the presence or absence of certain polymorph-
isms as potential predictor of CVD risk. Also a number
of studies have demonstrated that FH patients with
xanthomas have a higher risk of CVD compared to
those without them [40,41]. A recent meta-analysis has
demonstrated this fact concluding that the presence of
tendon xanthomas is associated with a 3 times higher
risk of CVD among FH patients, suggesting that xantho-
mas and CVD may share a common etiology [42]. Our
population had a 14.7% of global CVD prevalence, very
low if we compare it with another FH cohort as Simon
Broome [43], whose global prevalence was much higher
(60%). In Simon Broome cohort, 48% of FH patients
presented with tendon xanthomas; this fact could par-
tially justify the highest prevalence of CVD when we
compared it with our study where only 18.6% developed
them. This low prevalence of CVD could be explained
by the low presence of tendon xanthomas in our popu-
lation. On the other hand we should also considered
that Simon Broome cohort used clinical criteria for FH
diagnosis; in our cohort genetic diagnosis of FH was
carried out in all cases.
Among those potentially interesting genes of such
phenotypic variability is FVII gene. Several of its
polymorphisms have been associated with differences in
the risk of suffering CVD events when they have been
analyzed in groups of severe atherosclerosis patients
[18,19,23,24], basically due to variations in their levels
and plasma activity, which may encourage a state of
hypercoagulability [13,16]. Our study analyzed the dif-
ferent types of the R353Q polymorphism of FVII gene
in a sample of FH patients, comparing their potential
association with CVD (coronary, cerebrovascular and
peripheral artery disease). Some studies have suggested
that global CVD risk appears to be independent of the
R353Q polymorphism of FVII [44-46]; however, a meta-
analysis has demonstrated that bearers of the Q allele
are at lesser risk [47]. Furthermore, a lower rate of myo-
cardial infarcts has been observed in such populations
[23,24]. Several studies have described a reduction in
circulating FVII levels in patients who are heterozygous
(RQ) or homozygous (QQ) for the non-dominant gene
thus associating these levels with the presence of the Q
allele [13,14]. One study by Girelli et al. has even sug-
g e s t e dap o s s i b l ep r o t e c t i v ee f f e c to ft h i sa l l e l e ,a sa
means of explaining why patients with severe coronary
arteriosclerosis do not evolve acute myocardial infarct
[18]. In the face of these results, the data from our
study, in which the frequency distribution of the various
FVII alleles is identical to that of the general population
[33,48], do not shown any differences in terms of CVD
frequency between the subjects who are homozygous for
the various alleles when patients, with or without FH,
are compared. Although FH patients are at high risk of
CVD, they do not present differences in the frequency
of CVD events as a function of being carriers, or not, of
either allele. The fact that these patients present ele-
vated levels of total cholesterol and LDLc, and lower
levels of HDLc (these being factors that are independent
of the development of early-onset cardiovascular phe-
nomena), may have influenced our results, without such
findings having been observed in association with allele
Q. On the other hand, there was no causal relationship
between the carriers of the R allele, which determines
the most frequent genotype in the population, and
development of CVD.
Respecting plasma FVII Ag levels our data do not
shown differences in controls and FH patients and no
relation could be established with the genotype and also
with its allelic distribution (RR vs. RQ/QQ). These
results contrast with some studies that found lower FVII
levels in carriers of Q allele [13] and moreover no pro-
tective effect could be attributed to Q allele in our
population [14]. In the subgroup of patients affected of
FH, the comparison between those with or without
CVD showed no change in the adjusted mean levels of
FVII depending on genotype. All these circumstances
would support the absence of association between the
Table 5 FVII Ag levels in FH patients and CVD
CVD
No
(n = 80)
Yes
(n = 80)
Genotype
R353Q FVII
FVII levels
(ng/mL)
RR (n = 60) Mean 307.1 ± 175.4 278.6 ± 137.5
Adjusted mean 260.9 ± 240.0 311.7 ± 167.7
RQ/QQ (n = 20) Mean 219.7 ± 111.2 311.4 ± 135.5
Adjusted mean 213.3 ± 168.1 359.9 ± 152.3
Values expressed as means ± standard deviation. Analysis of variance for two
factors (CVD and genotype) adjusted for age, sex, diabetes mellitus, smoking
and arterial hypertension. No differences were found for the interaction
between both factors (0.97). CVD: cardiovascular disease. FVII: Factor VII.
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according to all those studies where global CVD risk
appears to be independent of the R353Q polymorphism
of FVII [44-46].
We must also consider, as one of the possible reasons
that could justify this lack of relation between the poly-
morphism and CVD, the low number of cardiovascular
events developed in our FH patients (14.7%), probably
because of their mean age, just 43.5 ± 16.3 with an age in
the first CV event of 46.7 ± 11.1 years. Jansen et al [49],
who investigated the contribution of polymorphisms in
multiple candidate genes to CVD risk, found a 33.1% of
CVD frequency in their FH cohort, where the mean age
of onset of CVD was 48.2 years, although they analyzed
patients with age at last visit of 56.4 ± 11.4 years.
Conclusions
We are unaware of any study that has associated FVII
with CVD risk in FH patients and our study is thus a
pioneer in this respect. It has been well demonstrated
that there are variations in the concentration and activ-
ity of FVII as a function of the genotype involved, with
these being lower in carriers of the Q allele. As our data
have shown, therefore, the R353Q polymorphism of
FVII gene does not predict cardiovascular risk in the
sample of FH patients in the Spanish Cohort.
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